REPL AdComm — Jul 30, 2026
Replimune Group · Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC).
Meeting dateJul 30, 2026
CommitteeCTGTAC
CompanyReplimune Group
DrugVusolimogene oderparepvec (RP1) + nivolumab
IndicationAdvanced melanoma
ApplicationBLA 125827
Primary sourceFDA Federal Register notice →
An advisory committee vote is a public panel review; it is advisory only — the FDA makes the final decision at the PDUFA date. All AdComm meetings →
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. © 2026 pdufa.bio